SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock Has Average Target Price of $12.00 According to Brokerages

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) have been given an average rating of “Moderate Buy” by the eleven analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $12.00.

A number of research analysts have recently commented on the company. Weiss Ratings raised SAB Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th. Wall Street Zen raised SAB Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, August 10th.

Institutional Trading of SAB Biotherapeutics

A number of institutional investors have recently modified their holdings of the business. Perceptive Advisors LLC grew its stake in SAB Biotherapeutics by 700.8% in the 1st quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company’s stock valued at $24,634,000 after buying an additional 5,628,533 shares in the last quarter. Seven Fleet Capital Management LP increased its position in shares of SAB Biotherapeutics by 47.2% during the second quarter. Seven Fleet Capital Management LP now owns 736,077 shares of the company’s stock valued at $2,871,000 after buying an additional 236,077 shares during the period. Affinity Asset Advisors LLC purchased a new stake in shares of SAB Biotherapeutics in the first quarter worth about $2,202,000. Monashee Investment Management LLC purchased a new stake in shares of SAB Biotherapeutics in the first quarter worth about $1,915,000. Finally, DV Trading LLC purchased a new stake in shares of SAB Biotherapeutics in the first quarter worth about $1,532,000. 7.82% of the stock is currently owned by hedge funds and other institutional investors.

SAB Biotherapeutics Trading Up 10.0%

NASDAQ SABS opened at $3.07 on Friday. SAB Biotherapeutics has a one year low of $2.44 and a one year high of $5.15. The business’s fifty day moving average is $3.29 and its 200-day moving average is $3.69.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.28). Equities analysts predict that SAB Biotherapeutics will post -1.17 EPS for the current year.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a biotechnology company focused on developing fully human polyclonal antibody medicines for infectious diseases, immune disorders and other conditions where targeted immune responses may provide therapeutic benefits. The company is based in Sioux Falls, South Dakota.

SAB Biotherapeutics uses its DiversitAb platform, which involves genetically engineered cattle capable of producing antibodies with human immune-system characteristics. Antibodies are collected from the animals’ plasma and processed for potential use as treatments, allowing the company to pursue antibody products without relying solely on conventional human donor sources.

The company has developed a pipeline that has included SAB-185, an investigational antibody therapy directed at SARS-CoV-2, as well as programs targeting influenza and autoimmune or immune-mediated diseases.